
    
      The specific objective of this study is to validate the Cayman Chemical serum thromboxane
      immunoassay as a measure of platelet production in healthy subjects who are treated with
      aspirin by demonstrating that the recovery of their serum thromboxane B2 levels occurs at a
      rate of about 10% per day after aspirin cessation.
    
  